Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

FDG PET/MR for the Assessment of Lymph Node Involvement in Lymphoma : Initial Results and Role of Diffusion-Weighted MR

Ivan Platzek, Bettina Beuthien-Baumann, Rainer Ordemann, Jens Maus, Georg Schramm, Hagen H. Kitzler, Michael Laniado, Jörg Kotzerke, Jörg van den Hoff

Original Research Article
Academic Radiology, In Press, Corrected Proof, Available online 30 July 2014


Rationale and Objectives

The purpose of this study was to evaluate the sensitivity and specificity of positron emission tomography/magnetic resonance imaging (PET/MR) with 18F-fluorodeoxyglucose (FDG) for nodal involvement in malignant lymphoma.

Materials and Methods

Twenty-seven patients with malignant lymphoma (16 men and 11 women; mean age, 45 years) were included in this retrospective study. The patients underwent FDG PET/MR after intravenous injection of FDG (176–357 MBq FDG, 282 MBq on average). Follow-up imaging and histology served as the standard of reference.


One-hundred and twenty-seven (18.1%) of 702 lymph node stations were rated as having lymphoma involvement based on the standard of reference. One-hundred and twenty-four (17.7%) of 702 lymph node stations were rated as positive by FDG PET/MR. The sensitivity and specificity of FDG PET/MR for lymph node station involvement were 93.8% and 99.4%.


FDG PET/MR is feasible for lymphoma staging and has a high sensitivity and specificity for nodal involvement in lymphoma. Comparison with PET/CT is necessary to determine whether FDG PET/MR can replace PET/CT for lymphoma staging.


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Search this site

Search form